| Literature DB >> 35745229 |
Carmen Herrera-Espiñeira1,2,3, María Del Carmen Martínez-Cirre4, Manuel López-Morales1,2,5, Antonia Lozano-Sánchez6, Antonia Rodríguez-Ruíz7, Laura Esther Salmerón-López8, María Isabel Gómez-Crespo9, Manuela Expósito-Ruíz10.
Abstract
INTRODUCTION: Obesity and overweight affect more than one-third of the world's population and pose a major public health problem.Entities:
Keywords: clinical trial; exercise; food habits; internal medicine; overweight; patients
Mesh:
Year: 2022 PMID: 35745229 PMCID: PMC9227976 DOI: 10.3390/nu14122499
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Flow chart of the study.
Comparison of characteristics between intervention and control groups.
| Variable | Intervention | Control | |
|---|---|---|---|
| Age (median (P25–P75)) | 69 (53.5–80) | 71.5 (58–81.75) | 0.140 |
| Sex (men) | 75 (53.2%) | 73 (55.3%) | 0.819 |
| Schooling | |||
| None | 37 (26.4%) | 43 (33.6%) | 0.419 |
| Primary | 68 (48.6%) | 58 (45.3%) | |
| Secondary/university | 35 (25%) | 27 (21.1%) | |
| Work situation | |||
| Unemployed | 15 (10.6%) | 11 (8.7%) | 0.651 |
| Actively employed/student | 28 (19.9%) | 21 (16.7%) | |
| Retired/permanent disability | 98 (69.5%) | 97 (74.6%) | |
| Municipality of residence | |||
| ≤20,000 inhabitants | 78 (54.3%) | 72 (55.4%) | 1 |
| >20,000 inhabitants | 63 (44.7%) | 58 (44.6%) | |
| Cohabitation (lives alone) | 21 (15.1%) | 13 (10.2%) | 0.315 |
| Smoker (yes) | 14 (9.9%) | 18 (14%) | 0.405 |
| Practices religion-based diet (yes) | 17 (13.2%) | 18 (16.4%) | 0.610 |
| Takes anti-depression drugs (yes) | 15 (10.9%) | 15 (11.8%) | 0.962 |
| Takes anxiolytics drugs (yes) | 16 (11.5%) | 13 (10.2%) | 0.892 |
| Concerning problems (yes) | 39 (27.9%) | 43 (34.4%) | 0.309 |
| Previous obesity program | 20 (14.4%) | 25 (19.8%) | 0.309 |
| Days of stay (median (P25–P75)) | 8 (6–10) | 8 (5–10.25) | 0.831 |
| Charlson (median (P25–P75)) | 2 (1–4) | 3 (2–5) | <0.001 |
| BMI (median (P25–P75)) | 31.2 (28.7–35.2) | 30.9 (28.7–34.7) | 0.545 |
| Weight at discharge (median (P25–P75)) | 84 (75.5–99) | 84 (75.2–99) | 0.638 |
| SBP after discharge (median (P25–P75)) | 130 (120–138) | 130 (120–137) | 0.223 |
| DBP after discharge (median (P25–P75)) | 75 (70–80) | 70 (65–80) | 0.012 |
Note: Percentages were calculated with reference to the total value available for each variable.
Distribution of diagnoses at admission (ICD-10).
| Diagnosis Grouping (ICD 10) | Group | Total | ||
|---|---|---|---|---|
| Intervention | Control | |||
| G1 Certain infectious and parasitic diseases (A00–B99) | Count | 6 | 1 | 7 |
| within group % | 4.3% | 0.8% | 2.6% | |
| G2 Neoplasms (C00–D49) | Count | 2 | 6 | 8 |
| within group % | 1.4% | 4.5% | 2.9% | |
| G3 Diseases of the blood and blood-forming | Count | 4 | 0 | 4 |
| within group % | 2.8% | 0.0% | 1.5% | |
| G4 Endocrine, nutritional, and metabolic | Count | 4 | 1 | 5 |
| within group % | 2.8% | 0.8% | 1.8% | |
| G6 Other diseases of organs and body systems (G00–N99) | Count | 102 | 106 | 208 |
| within group % | 72.3% | 80.3% | 76.2% | |
| G9 Various groups (R00–Z99) | Count | 23 | 18 | 41 |
| within group % | 16.3% | 13.6% | 15.0% | |
| Total | Count | 141 | 132 | 273 |
| within group % | 100% | 100% | 100% | |
ICD 10: 10th revision of the International Classification of Diseases. G6 includes diseases with codes G00–G99, H00–H59, I00–I99, J00–J99, K00–K95, L00–L99, and M00–M99.
Comparison of outcome variables between baseline and three months.
| Variable |
| Baseline | 3 Months | |||
|---|---|---|---|---|---|---|
| Weight after discharge | ||||||
| Intervention | 88 | 87.62 ± 19.23 | 84.09 ± 16.59 | <0.001 | 0.617 | 0.170 |
| Control | 69 | 85.31 ± 18.65 | 83.54 ± 18.28 | |||
| SBP after discharge | ||||||
| Intervention | 62 | 133.72 ± 19.60 | 109.37 ± 37.71 | <0.001 | 0.187 | <0.001 |
| Control | 57 | 127.42 ± 15.93 | 124.68 ± 13.94 | |||
| DBP after discharge | ||||||
| Intervention | 62 | 73.43 ± 15.06 | 63.90 ± 22.05 | 0.009 | 0.066 | 0.042 |
| Control | 57 | 73.17 ± 12.07 | 71.93 ± 11.25 | |||
| EQ-5D-5L value | ||||||
| Intervention | 90 | 0.71 ± 0.27 | 0.68 ± 0.30 | 0.035 | 0.589 | 0.563 |
| Control | 70 | 0.71 ± 0.24 | 0.65 ± 0.26 | |||
| VAS score (EQ-5D-5L) | ||||||
| Intervention | 84 | 58.19 ± 18.47 | 62.74 ± 22.63 | 0.046 | 0.310 | 0.983 |
| Control | 69 | 55.65 ± 20.93 | 60.10 ± 21.18 | |||
| Pardo Questionnaire | ||||||
| CC dimension | ||||||
| Intervention | 83 | 2.21 ± 0.69 | 2.95 ± 0.68 | <0.001 | 0.174 | 0.212 |
| Control | 63 | 2.17 ± 0.60 | 2.73 ± 0.88 | |||
| PW dimension | ||||||
| Intervention | 87 | 3.72 ± 1.07 | 4.03 ± 0.97 | 0.399 | 0.376 | 0.030 |
| Control | 68 | 4.06 ± 1.04 | 3.93 ± 1.01 | |||
| PE dimension | ||||||
| Intervention | 87 | 1.77 ± 0.92 | 1.78 ± 0.89 | 0.121 | 0.177 | 0.161 |
| Control | 68 | 1.79 ± 0.96 | 2.09 ± 1.20 | |||
| HD dimension | ||||||
| Intervention | 82 | 3.48 ± 0.57 | 4.40 ± 1.10 | <0.001 | 0.881 | 0.017 |
| Control | 64 | 3.67 ± 0.59 | 4.19 ± 0.51 | |||
| AC dimension | ||||||
| Intervention | 88 | 3.45 ± 0.73 | 3.51 ± 0.79 | 0.133 | 0.406 | 0.021 |
| Control | 70 | 3.56 ± 0.76 | 3.26 ± 0.46 | |||
Time*Group Effect = Between-group difference taking into account the time between baseline and three.month.
Comparison of outcome variables between baseline and six months.
| Variable |
| Baseline | 6 Months | |||
|---|---|---|---|---|---|---|
| Weight after discharge | ||||||
| Intervention | 85 | 89.93 ± 20.99 | 85.73 ± 19.09 | <0.001 | 0.095 | 0.361 |
| Control | 65 | 84.45 ± 14.76 | 81.74 ± 13.91 | |||
| SBP after discharge | ||||||
| Intervention | 58 | 128.55 ± 15.01 | 121.41 ± 17.17 | 0.012 | 0.886 | 0.294 |
| Control | 53 | 126.09 ± 14.14 | 123.11 ± 21.95 | |||
| DBP after discharge | ||||||
| Intervention | 57 | 75.18 ± 10.38 | 67.79 ± 19.25 | 0.012 | 0.607 | 0.164 |
| Control | 53 | 71.58 ± 9.85 | 69.42 ± 14.15 | |||
| EQ-5D-5L value | ||||||
| Intervention | 86 | 0.71 ± 0.28 | 0.62 ± 0.34 | 0.001 | 0.482 | 0.970 |
| Control | 68 | 0.74 ± 0.25 | 0.65 ± 0.28 | |||
| VAS score (EQ-5D-5L) | ||||||
| Intervention | 82 | 56.8 ± 20.01 | 63.32 ± 23.09 | 0.018 | 0.451 | 0.587 |
| Control | 68 | 55.96 ± 20.58 | 60.06 ± 21.55 | |||
| Pardo Questionnaire | ||||||
| CC dimension | ||||||
| Intervention | 81 | 2.22 ± 0.74 | 2.84 ± 0.71 | <0.001 | 0.931 | 0.827 |
| Control | 65 | 2.21 ± 0.62 | 2.86 ± 0.99 | |||
| PW dimension | ||||||
| Intervention | 83 | 3.81 ± 1.05 | 3.84 ± 1.03 | 0.374 | 0.068 | 0.545 |
| Control | 63 | 4 ± 1.08 | 4.15 ± 0.87 | |||
| PE dimension | ||||||
| Intervention | 82 | 1.72 ± 0.94 | 2.07 ± 1.1 | 0.006 | 0.622 | 0.601 |
| Control | 66 | 1.85 ± 1.05 | 2.09 ± 1.32 | |||
| HD dimension | ||||||
| Intervention | 76 | 3.48 ± 0.62 | 4.2 ± 0.55 | <0.001 | 0.101 | 0.755 |
| Control | 61 | 3.65 ± 0.62 | 4.33 ± 1.02 | |||
| AC dimension | ||||||
| Intervention | 83 | 3.42 ± 0.65 | 3.4 ± 0.63 | 0.065 | 0.970 | 0.106 |
| Control | 68 | 3.55 ± 0.79 | 3.28 ± 0.54 | |||
Time*Group Effect = Between-group difference taking into account the time between baseline and six-month.
Comparison of outcome variables between baseline and 12 months.
| Variable |
| Baseline Mean ± SD | 12 Months | |||
|---|---|---|---|---|---|---|
| Weight after discharge | ||||||
| Intervention | 73 | 87.87 ± 20.51 | 84.72 ± 17.58 | <0.001 | 0.314 | 0.742 |
| Control | 66 | 84.98 ± 20.31 | 81.25 ± 18.45 | |||
| SBP after discharge | ||||||
| Intervention | 47 | 127.43 ± 12.91 | 121.28 ± 15.23 | 0.003 | 0.607 | 0.552 |
| Control | 43 | 127.56 ± 11.77 | 123.42 ± 12.21 | |||
| DBP after discharge | ||||||
| Intervention | 46 | 74.96 ± 8.64 | 70.76 ± 10.79 | 0.058 | 0.794 | 0.141 |
| Control | 43 | 72.69 ± 8.64 | 72.16 ± 10.28 | |||
| EQ-5D-5L value | ||||||
| Intervention | 74 | 0.74 ± 0.28 | 0.61 ± 0.35 | <0.001 | 0.975 | 0.315 |
| Control | 66 | 0.71 ± 0.26 | 0.64 ± 0.33 | |||
| VAS score (EQ-5D-5L) | ||||||
| Intervention | 73 | 57.51 ± 19.25 | 59.30 ± 24.35 | 0.757 | 0.911 | 0.688 |
| Control | 64 | 58.2 ± 18.86 | 57.97 ± 25.54 | |||
| Pardo Questionnaire | ||||||
| CC dimension | ||||||
| Intervention | 66 | 2.3 ± 0.73 | 3.20 ± 0.95 | <0.001 | 0.415 | 0.699 |
| Control | 57 | 2.23 ± 0.63 | 3.07 ± 0.95 | |||
| PW dimension | ||||||
| Intervention | 72 | 3.94 ± 0.97 | 4.09 ± 0.87 | 0.151 | 0.05 | 0.941 |
| Control | 61 | 4.17 ± 0.92 | 4.32 ± 0.82 | |||
| PE dimension | ||||||
| Intervention | 71 | 1.8 ± 0.97 | 1.87 ± 1.32 | 0.735 | 0.703 | 0.830 |
| Control | 63 | 1.89 ± 1.07 | 1.91 ± 1.45 | |||
| HD dimension | ||||||
| Intervention | 68 | 3.41 ± 0.63 | 4.15 ± 0.66 | <0.001 | 0.03 | 0.626 |
| Control | 59 | 3.68 ± 0.618 | 4.35 ± 0.41 | |||
| AC dimension | ||||||
| Intervention | 72 | 3.37 ± 0.712 | 3.29 ± 0.41 | 0.501 | 0.432 | 0.213 |
| Control | 64 | 3.61 ± 0.79 | 3.27 ± 0.48 | |||
Time*Group Effect = Between-group difference taking into account the time between baseline and twelve-month.
Comparison of readmissions, emergency department visits, and deaths during the follow-up.
| Variable | 0–3 Months | 3–6 Months | 6–12 Months | |||
|---|---|---|---|---|---|---|
|
| ||||||
|
| Readmissions |
| Readmissions |
| Readmissions | |
| Intervention | 125 | 32 (25.6%) | 113 | 12 (10.6) | 104 | 18 (17.3%) |
| Control | 111 | 25 (22.5%) | 96 | 10 (10.4%) | 92 | 20 (21.7%) |
|
| ||||||
|
| Visits to the emergency department |
| Visits to the emergency department |
| Visits to the emergency department | |
| Intervention | 125 | 47 (37.6%) | 113 | 29 (25.7%) | 104 | 26 (25%) |
| Control | 111 | 38 (34.2%) | 96 | 27 (27.6%) | 92 | 26 (28.3%) |
|
| ||||||
|
| Deaths |
| Deaths |
| Deaths | |
| Intervention | 125 | 9 (7.4%) | 113 | 9 (8%) | 104 | 9 (8.7%) |
| Control | 111 | 16 (14.5%) | 96 | 4 (4.2%) | 92 | 5 (5.4%) |
CCI ≥ 3. Comparison between baseline and 12 months (n = 151).
| Variable |
| Baseline | 12 Months | |||
|---|---|---|---|---|---|---|
| Weight after discharge | ||||||
| Intervention | 27 | 83.75 ± 16.80 | 83.63 ± 17.04 | 0.069 | 0.220 | 0.0893 |
| Control | 48 | 80.43 ± 18.83 | 76.95 ± 15.95 | |||
| SBP after discharge | ||||||
| Intervention | 19 | 130.63 ± 15.55 | 121.05 ± 15.60 | 0.001 | 0.826 | 0.407 |
| Control | 34 | 128.03 ± 12.98 | 122.26 ± 11.67 | |||
| DBP after discharge | ||||||
| Intervention | 19 | 75.74 ± 7.30 | 70.53 ± 12.35 | 0.046 | 0.427 | 0.121 |
| Control | 34 | 71.65 ± 8.69 | 70.97 ± 9.22 | |||
| EQ-5D-5L value | ||||||
| Intervention | 27 | 0.61 ± 0.31 | 0.43 ± 0.34 | 0.001 | 0.098 | 0.267 |
| Control | 48 | 0.67 ± 0.25 | 0.58 ± 0.32 | |||
| VAS score (EQ-5D-5L) | ||||||
| Intervention | 26 | 52.43 ± 17.28 | 56.04 ± 24.26 | 0.514 | 0.341 | 0.667 |
| Control | 47 | 57.55 ± 18.62 | 58.30 ± 22.58 | |||
| Pardo Questionnaire | ||||||
| CC dimension | ||||||
| Intervention | 25 | 2.42 ± 0.57 | 3.53 ± 0.92 | <0.001 | 0.086 | 0.163 |
| Control | 44 | 2.28 ± 0.67 | 3.07 ± 0.98 | |||
| PW dimension | ||||||
| Intervention | 26 | 4.10 ± 1.05 | 4.29 ± 0.81 | 0.431 | 0.447 | 0.615 |
| Control | 47 | 4.29 ± 0.83 | 4.33 ± 0.79 | |||
| PE dimension | ||||||
| Intervention | 25 | 1.73 ± 0.90 | 1.57 ± 1.22 | 0.644 | 0.307 | 0.968 |
| Control | 46 | 1.99 ± 1.12 | 1.82 ± 1.42 | |||
| HD dimension | ||||||
| Intervention | 25 | 3.81 ± 0.47 | 4.26 ± 0.58 | <0.001 | 0.711 | 0.313 |
| Control | 43 | 3.75 ± 0.59 | 4.39 ± 0.40 | |||
| AC dimension | ||||||
| Intervention | 26 | 3.40 ± 0.87 | 3.17 ± 0.37 | 0.005 | 0.352 | 0.519 |
| Control | 47 | 3.59 ± 0.79 | 3.22 ± 0.45 | |||
Time*Group Effect = Between-group difference taking into account the time between baseline and twelve-month.